为预测宫腺癌的整体存活率开发和验证名图:基于人口的研究
Xin-Yu Fa1, Yong-Jing Yang2, Chun-Cao Niu1
1Department of Oncology and Hematology, China-Japan Union Hospital of Jilin University, Changchun, China.
Medicine
|November 28, 2023
概括
一个新的诺米图准确地预测了宫腺癌 (CAC) 患者的整体存活率. 与FIGO分期系统相比,该工具提供了更好的歧视和临床实用性,用于CAC预后.
科学领域:
- 在瘤学瘤学.
- 医学统计 医学统计
背景情况:
- 宫腺癌 (CAC) 预后预测对于患者管理至关重要.
- 现有的分期系统在预测CAC患者的整体存活率方面可能缺乏准确性.
研究的目的:
- 开发和验证用于预测宫腺癌患者的整体存活率的诺姆图.
- 为了与国际妇科和产科联合会 (FIGO) 的分类系统比较名图的预测性能.
主要方法:
- 利用了来自监测,流行病学和最终结果 (SEER) 计划 (2004-2015) 的大量数据集.
- 应用了考克斯回归建模来确定CAC的独立预后因素.
- 构建并验证了一个包含年龄,婚姻状况,瘤大小,等级,FIGO分类,淋巴结转移,手术和化疗的诺姆图.
主要成果:
- 与FIGO分阶段系统相比,名图显示出更高的区分和校准.
- 多变量分析确定了关键预测因素,包括年龄,瘤大小,等级,FIGO阶段和治疗方式.
- 决策曲线分析证实了名图的高临床效用和有利的5年生存预测.
结论:
- 开发的诺米图为预测CAC患者的整体存活率提供了强大的和临床上有用的工具.
- 这种名录图比传统的FIGO分类提供了更高的预测准确度.
- 这些发现表明,在宫腺癌的护理中,有可能改善患者分层和治疗规划.
相关概念视频
Cancer Survival Analysis
356
Cancer survival analysis focuses on quantifying and interpreting the time from a key starting point, such as diagnosis or the initiation of treatment, to a specific endpoint, such as remission or death. This analysis provides critical insights into treatment effectiveness and factors that influence patient outcomes, helping to shape clinical decisions and guide prognostic evaluations. A cornerstone of oncology research, survival analysis tackles the challenges of skewed, non-normally...
356
Comparing the Survival Analysis of Two or More Groups
197
Survival analysis is a cornerstone of medical research, used to evaluate the time until an event of interest occurs, such as death, disease recurrence, or recovery. Unlike standard statistical methods, survival analysis is particularly adept at handling censored data—instances where the event has not occurred for some participants by the end of the study or remains unobserved. To address these unique challenges, specialized techniques like the Kaplan-Meier estimator, log-rank test, and...
197
Kaplan-Meier Approach
152
The Kaplan-Meier estimator is a non-parametric method used to estimate the survival function from time-to-event data. In medical research, it is frequently employed to measure the proportion of patients surviving for a certain period after treatment. This estimator is fundamental in analyzing time-to-event data, making it indispensable in clinical trials, epidemiological studies, and reliability engineering. By estimating survival probabilities, researchers can evaluate treatment effectiveness,...
152


